International consensus guidance for management of myasthenia gravis: Executive summary

DSpace/Manakin Repository

International consensus guidance for management of myasthenia gravis: Executive summary

Citable link to this page

 

 
Title: International consensus guidance for management of myasthenia gravis: Executive summary
Author: Sanders, Donald B.; Wolfe, Gil I.; Benatar, Michael; Evoli, Amelia; Gilhus, Nils E.; Illa, Isabel; Kuntz, Nancy; Massey, Janice M.; Melms, Arthur; Murai, Hiroyuki; Nicolle, Michael; Palace, Jacqueline; Richman, David P.; Verschuuren, Jan; Narayanaswami, Pushpa

Note: Order does not necessarily reflect citation order of authors.

Citation: Sanders, D. B., G. I. Wolfe, M. Benatar, A. Evoli, N. E. Gilhus, I. Illa, N. Kuntz, et al. 2016. “International consensus guidance for management of myasthenia gravis: Executive summary.” Neurology 87 (4): 419-425. doi:10.1212/WNL.0000000000002790. http://dx.doi.org/10.1212/WNL.0000000000002790.
Full Text & Related Files:
Abstract: Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
Published Version: doi:10.1212/WNL.0000000000002790
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977114/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002396
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters